Mesoblast (ASX:MSB) said 21 of the first 25, or 84%, patients treated with its Ryoncil product in a "real-world" clinical setting post-launch were alive and completed the initial 28-day treatment regimen as per the US Food and Drug Administration (FDA) approval label, according to a Tuesday Australian bourse filing.

The four remaining patients had been offered and failed other therapies before the use of Ryoncil and died of severe steroid-refractory acute graft-versus-host disease within 28 days, per the filing.

The firm established a patient access hub termed MyMesoblast to allow patients to order Ryoncil. It has onboarded 45 transplant centers, and it is targeting the onboarding of 64 centers.

Its shares fell nearly 1% in recent trading on Tuesday.